CLYM vs. SVRA, PHVS, OMER, EBS, STOK, MLYS, RAPP, PHAT, XERS, and RNAC
Should you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Savara (SVRA), Pharvaris (PHVS), Omeros (OMER), Emergent BioSolutions (EBS), Stoke Therapeutics (STOK), Mineralys Therapeutics (MLYS), Rapport Therapeutics (RAPP), Phathom Pharmaceuticals (PHAT), Xeris Biopharma (XERS), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Climb Bio vs.
Climb Bio (NASDAQ:CLYM) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
In the previous week, Savara had 2 more articles in the media than Climb Bio. MarketBeat recorded 2 mentions for Savara and 0 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.84 beat Savara's score of 0.47 indicating that Climb Bio is being referred to more favorably in the media.
69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 3.2% of Climb Bio shares are owned by company insiders. Comparatively, 5.1% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Climb Bio has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
Climb Bio's return on equity of -42.21% beat Savara's return on equity.
Savara is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.
Climb Bio currently has a consensus price target of $10.00, indicating a potential upside of 431.91%. Savara has a consensus price target of $9.86, indicating a potential upside of 252.04%. Given Climb Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Climb Bio is more favorable than Savara.
Savara received 298 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 66.82% of users gave Savara an outperform vote.
Summary
Climb Bio beats Savara on 9 of the 16 factors compared between the two stocks.
Get Climb Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Climb Bio Competitors List
Related Companies and Tools
This page (NASDAQ:CLYM) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CLYM Stock Alerts